Posts tagged research

In the market for prime pharmaceutical space in Wlimington, DE? AstraZeneca sold another sprawling research outpost in its global reorganization

In the market for prime pharmaceutical space in Wlimington, DE? AstraZeneca sold another sprawling research outpost in its global reorganization

Pharmas collaborating increasingly with universities. Novartis and the University of Pennsylvania announced a research and licensing agreement that aims to bring to market a new approach to fighting cancer that has shown promising results in early trials.

Pharmas collaborating increasingly with universities. Novartis and the University of Pennsylvania announced a research and licensing agreement that aims to bring to market a new approach to fighting cancer that has shown promising results in early trials.

Sad news continues for pharmaceutical companies. Three leading pharmaceutical companies announced disappointing news from clinical tests on drugs they had hoped would  turn out to be big sellers.

Sad news continues for pharmaceutical companies. Three leading pharmaceutical companies announced disappointing news from clinical tests on drugs they had hoped would turn out to be big sellers.

Giving advice to pharmaceutical companies. Pharma executives are seeking input from the people who hold the purse  strings earlier than ever in the clinical research process, in some  cases five years or more before regulators would even look at a product,  executives told Reuters.

Giving advice to pharmaceutical companies. Pharma executives are seeking input from the people who hold the purse strings earlier than ever in the clinical research process, in some cases five years or more before regulators would even look at a product, executives told Reuters.

Merck looking for growth, plans to invest $1 billion in Singapore.

Merck looking for growth, plans to invest $1 billion in Singapore.

Medicine will suffer if Washington controls the flow of scientific information

Scott Gottlieb’s Op-Ed in the WSJ

The bottom line is that Washington is attempting to reduce health-care spending by constraining the speech of private firms that promote pricey drugs while promoting government research that discourages their use. The advance of medical practice will suffer if Washington can decide the standards for medical decision-making and control the flow of scientific information.

Read the Op-Ed here